Prime Global and Raremark® form strategic partnership to transform solutions and outcomes for patients with rare diseases
January 2021The expertise and heritage of two award-winning companies have been brought together to form a strategic partnership with patient outcomes at the heart
For release from 21 January 2021
Medical communications company, Prime Global, and healthcare technology company, Raremark®, announced today that they have formed a strategic partnership to transform solutions for patients with rare diseases. Together, the companies will uncover insights into the entire patient journey that will allow the creation of truly patient-centric drug development and commercialisation programs. Focusing on the needs of patients is the key to powerful communications that make a tangible difference to patient outcomes.
Raremark is the first of its kind patient experience network in rare disease with its patient-powered knowledge platform, Xperiome, providing a robust foundation of patient insights to deliver innovative new therapies faster and smarter for the pharmaceutical industry. Building a community for people affected by rare conditions, sharing knowledge, and collecting real-world experience data, brings together patients and researchers to improve the lives of others. Prime Global, founded in 1997, is a medical communications and market access group leading the way in pharmaceutical and biotech marcomms.
Graeme Peterson, CEO of Prime Global, said: “Our strategic partnership enables laser focus in patient engagement for patients with rare diseases. By combining Raremark’s cutting-edge Xperiome platform for patients with our 23 years of award-winning medical communications experience, we can deliver patient-centric services and solutions that improve outcomes for both pharma and, most importantly, patients.”
Jeremy Edwards, Raremark’s CEO, said: “This exciting new collaboration with Prime Global provides a strategic foundation that will allow us to deliver significant value to our clients through our combined expertise. It will engage, empower and educate patients - ultimately gaining a deeper insight into their requirements to improve lives and accelerate the development and reach of new treatments.”
Peterson added, “Working closely with patients is vital and the bedrock of the services we develop for our clients. Raremark is at the forefront of innovation in patient engagement and our ability to collaborate brings new and exciting capabilities."
Prime Global has experienced exceptional organic growth in recent years, including the recent launch of Prime Access, a Market Access consultancy, and IRIS, a strategic consultancy. The company is proud to rank on several business growth lists such as the Sunday Times Fast Track 100 in 2018 and 2019, and of being selected as consultancy growth winners of the Alantra Fast Pharma 50 in 2019 and 2020.
About Prime Global
Our highly qualified scientific teams deliver expertise across a wide range of therapy areas such as oncology, cardiovascular, diabetes and metabolic disorders, central nervous system and neurosciences, respiratory, infectious diseases, vaccines, HIV and virology, devices and diagnostics, sexual health and urology, nephrology, haematology, dermatology, gastrointestinal, rare and genetic disorders, and immuno-inflammation and allergy.
We believe passionately in the value of innovative and creative science communication to further our understanding of the world, and to benefit patients everywhere. Our philosophy is ‘people first’. People are at the heart of everything we do, from the colleagues we work with to the clients we support every day, and ultimately the patients helped by their products and services.
Sign up for updates
If you’re an industry professional and would like to subscribe to updates from our research team, including our research projects and our Rare Opinion blog, fill in your details below and we’ll add you to our mailing list.